Amgen looks to jump-start academic research; Bayer eyes animal health deals;

@FierceBiotech: Buzz: Cellectis could be in a line for a $1.6B Pfizer buyout. Article | Follow @FierceBiotech

@JohnCFierce: Is this a good time to tout my survey (with Bloomberg Intelligence)? Are biotech assets overvalued? Check it out | Follow @JohnCFierce

> Amgen ($AMGN) is offering up a catalog of research tools and reagents to academic institutions with the goal of jump-starting projects in biology, launching the Amgen Biology-Enabling Resource, or AmBER. News

> Bayer's impending move to spin off its plastics business is soon to give the drugmaker a large cash sum, and CEO Marijn Dekkers said the company may splurge to bolster its animal health division. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: Deerfield backs startup with $10M for its hemodialysis vascular access implant. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ info from the company: CareFusion's Avea ventilator recalled as potentially deadly. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific slapped with $100M verdict in vaginal mesh suit. News | Follow @EmilyWFierce

> Zimmer ($ZMH) to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close. More

> Nonprofit leads $17.5M round for medical image exchange startup LifeImage. Article

Pharma News

@FiercePharma: Tech makers market health wearables to dog owners. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Lundbeck's EU lobbying yields political boost for anti-alcohol med Selincro. Article | Follow @CarlyHFierce

> Bayer chief may plow spinoff cash into animal health buys. Article

> Betting on Pfizer ($PFE) merger--or CEO goodbye--traders go bullish on Glaxo ($GSK). Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.